🧠 Ginkgo Biloba Research — Clinical Evidence Database, EGb 761 Studies & Dosing Protocols
> **Quick Answer / TL;DR**
>
> - **EGb 761 (240 mg/day)** is the gold-standard ginkgo extract — a 2025 meta-analysis confirmed it significantly improves cognition, daily functioning, and quality of life in mild dementia [1]
> - **24/6 standardization** (24% flavone glycosides, 6% terpene lactones, <5 ppm ginkgolic acid) is the only reliable extract profile — unstandardized products are unreliable [2]
> - **⚠️ CRITICAL:** Ginkgo increases bleeding risk with warfarin (HR 1.38), aspirin, and other blood thinners — never combine without medical supervision [3][4]
> - **8–12 weeks** required for cognitive effects; circulatory symptoms may improve in 2–4 weeks
> - **Strong evidence** for mild dementia and vascular cognitive impairment; **weak evidence** for cognitive enhancement in healthy adults [5]
> - Read the full [HealthSecrets ginkgo biloba guide](https://healthsecrets.com/mental-wellness/ginkgo-biloba-brain-health) for a complete evidence-based review
Table of Contents
- Clinical Evidence Database by Condition
- EGb 761 Clinical Trials Database
- Drug Interaction Reference Table
- Dosing Protocols by Use Case
- Quality Standards — 24/6 Standardization
- Product Comparison
- Mechanisms of Action
- Curated PubMed Research Library
- Frequently Asked Questions
- References
- Free Tools & Related Resources
Clinical Evidence Database by Condition
Ginkgo biloba has been studied across multiple neurological and vascular conditions. Below is a curated database of clinical evidence organized by condition, with evidence grades based on the quality and quantity of available research.
| Condition | Evidence Grade | Key Findings | Key Studies |
|---|---|---|---|
| Mild-to-moderate dementia | A — Strong | EGb 761 240 mg/day significantly improves cognition (ADAS-cog), daily functioning, and caregiver distress. Meta-analyses confirm clinically meaningful benefits. | [1][2][5] |
| Vascular cognitive impairment | A — Strong | Particularly effective for dementia with a vascular component. Improves cerebral blood flow, reduces oxidative stress markers. | [1][6] |
| Mild cognitive impairment (MCI) | A — Strong | 2024 study in amyloid PET-positive MCI patients: ginkgo preserved cognition, improved daily functioning, reduced plasma Aβ oligomerization. | [7] |
| Cerebrovascular insufficiency | B — Moderate | Improves dizziness, tinnitus, and headache associated with poor cerebral circulation. Evidence from multiple European trials. | [2][6] |
| Age-related cognitive decline | B — Moderate | May slow cognitive decline in older adults, especially with vascular risk factors. Benefits modest in healthy aging. | [5][8] |
| Tinnitus (vascular origin) | B — Moderate | May help tinnitus caused by poor inner ear circulation. Limited benefit for non-vascular tinnitus. | [9] |
| Intermittent claudication | B — Moderate | Improves pain-free walking distance in peripheral arterial disease. Cochrane review found modest benefits. | [10] |
| Vertigo (vascular origin) | B — Moderate | Improves vestibular symptoms related to cerebrovascular insufficiency. | [2] |
| Alzheimer’s prevention (healthy) | C — Weak | GEM trial (n=3,069) found no benefit for dementia prevention in healthy older adults over 6+ years. | [11] |
| Cognitive enhancement (healthy young adults) | C — Weak | No convincing evidence for cognitive improvement in healthy adults under 60. | [12] |
| Macular degeneration | C — Preliminary | Small studies suggest possible benefit for age-related macular degeneration. Needs larger trials. | [13] |
| Evidence Grade Key: A = Multiple RCTs and/or meta-analyses | B = Consistent RCT results | C = Preliminary/observational only |
EGb 761 Clinical Trials Database
EGb 761 is the specific proprietary ginkgo extract used in virtually all major clinical trials. It is manufactured by Dr. Willmar Schwabe Pharmaceuticals and standardized to 24% flavone glycosides and 6% terpene lactones. Below is a curated database of landmark EGb 761 trials.
Landmark Meta-Analyses & Systematic Reviews
| Study | Year | Journal | n | Key Finding |
|---|---|---|---|---|
| Müller WE, et al. | 2025 | World J Biol Psychiatry | Meta-analysis | EGb 761 is safe and effective in mild dementia; significant improvements in cognition, daily functioning, and quality of life [1] |
| Ong Lai Teik D, et al. | 2024 | J Neuropsychiatry | Systematic review | Ginkgo biloba demonstrates benefits in neuropsychiatric disorders; EGb 761 most studied extract [2] |
| Nguyen TH, et al. | 2025 | PLOS ONE | Comprehensive analysis | Significant drug interactions affecting bleeding risk and coagulation profiles confirmed [4] |
| DeKosky ST, et al. (GEM) | 2008 | JAMA | 3,069 | No benefit for dementia prevention in healthy older adults over median 6.1 years [11] |
Key Individual RCTs
| Study | Year | Population | Dose | Duration | Outcome |
|---|---|---|---|---|---|
| Kim HJ, et al. | 2024 | Amyloid PET+ MCI patients | 240 mg/day | 12 months | Preserved cognition, improved daily functioning, reduced plasma Aβ oligomerization [7] |
| Ihl R, et al. | 2012 | Dementia with BPSD | 240 mg/day | 24 weeks | Significant improvement in NPI, SKT, and ADL scores vs placebo [14] |
| Herrschaft H, et al. | 2012 | Dementia with neuropsychiatric symptoms | 240 mg/day | 24 weeks | EGb 761 improved cognition and behavioral symptoms [15] |
| Napryeyenko O, et al. | 2007 | Dementia + neuropsychiatric features | 240 mg/day | 22 weeks | Significant improvements in SKT, NPI, and activities of daily living [16] |
| Kanowski S, et al. | 1996 | Mild-moderate dementia | 240 mg/day | 24 weeks | Clinically meaningful improvement in CGI and SKT scores vs placebo [17] |
⚠️ Important context: Most positive EGb 761 trials were funded by Dr. Willmar Schwabe Pharmaceuticals. While the research methodology is generally sound, industry funding should be considered when evaluating the evidence. The independently funded GEM trial found no preventive benefit in healthy adults [11].
Drug Interaction Reference Table
Ginkgo’s antiplatelet effects (PAF antagonism by ginkgolides) create clinically significant interactions with multiple drug classes. This reference table is designed for quick clinical lookup.
HIGH RISK — Do Not Combine Without Medical Supervision
| Drug Class | Specific Drugs | Risk Level | Mechanism | Evidence |
|---|---|---|---|---|
| Anticoagulants | Warfarin, apixaban, rivaroxaban, dabigatran, enoxaparin | 🔴 HIGH | Additive anticoagulant effect via PAF antagonism + vitamin K interference | VA study: HR 1.38 (95% CI: 1.20–1.58) for bleeding events [3] |
| Antiplatelets | Clopidogrel, aspirin, ticagrelor, prasugrel, dipyridamole | 🔴 HIGH | Synergistic platelet aggregation inhibition | PLOS ONE 2025 comprehensive analysis [4] |
| NSAIDs (chronic use) | Ibuprofen, naproxen, celecoxib, diclofenac, meloxicam | 🔴 MODERATE-HIGH | Additive GI bleeding risk + antiplatelet effects | Case reports of spontaneous bleeding [4][18] |
MODERATE RISK — Monitor Closely
| Drug Class | Specific Drugs | Risk Level | Mechanism | Notes |
|---|---|---|---|---|
| SSRIs | Fluoxetine, sertraline, paroxetine, citalopram, escitalopram | ⚠️ MODERATE | SSRIs impair platelet function; additive bleeding risk with ginkgo | Monitor for unusual bruising/bleeding [4] |
| SNRIs | Venlafaxine, duloxetine | ⚠️ MODERATE | Similar mechanism to SSRIs | Monitor for bleeding signs |
| Anticonvulsants | Valproate, carbamazepine, phenytoin | ⚠️ MODERATE | CYP enzyme modulation may alter drug levels | Consult physician before combining |
| Antihypertensives | ACE inhibitors, ARBs, calcium channel blockers | ⚠️ LOW-MODERATE | Additive hypotensive effect via vasodilation | Monitor blood pressure |
| Diabetes medications | Insulin, metformin, sulfonylureas | ⚠️ LOW-MODERATE | Ginkgo may affect blood glucose levels | Monitor blood glucose more frequently |
Pre-Surgical Protocol
| Timeframe | Action |
|---|---|
| 2 weeks before surgery | Stop all ginkgo supplementation |
| Day of procedure | Confirm ginkgo has been discontinued |
| Post-surgery | Resume only after clearance from surgeon |
| Dental procedures | Same 2-week discontinuation protocol |
Dosing Protocols by Use Case
Most major clinical trials used EGb 761 at 120–240 mg/day, with 240 mg daily being the most studied dose for cognitive outcomes. Below are evidence-based dosing protocols organized by therapeutic goal.
| Use Case | Daily Dose | Protocol | Duration | Evidence |
|---|---|---|---|---|
| Starting dose / tolerance assessment | 120 mg | Once daily with food | 1–2 weeks | Standard practice |
| Mild cognitive impairment | 240 mg | 120 mg twice daily | 12+ weeks minimum | Grade A [1][7] |
| Mild-to-moderate dementia | 240 mg | 120 mg twice daily | 6–12 months (trial durations) | Grade A [1][14][15] |
| Vascular cognitive impairment | 240 mg | 120 mg twice daily | 12+ weeks | Grade A [1][6] |
| Cerebrovascular insufficiency | 120–240 mg | Divided doses | 2–4 weeks for initial effects | Grade B [2] |
| Tinnitus (vascular) | 240 mg | 120 mg twice daily | 12 weeks minimum | Grade B [9] |
| Intermittent claudication | 120–240 mg | Divided doses | 8–12 weeks | Grade B [10] |
| Maximum recommended dose | 240 mg | — | — | No additional benefits above 240 mg |
Dosing Timeline: What to Expect
| Phase | Timeframe | Expected Effects |
|---|---|---|
| Tolerance assessment | Weeks 1–2 | Assess for headache, GI upset, dizziness. Minimal cognitive changes. |
| Early response | Weeks 2–4 | Possible improvement in circulatory symptoms (dizziness, tinnitus). |
| Cognitive response | Weeks 8–12 | Cognitive benefits may become noticeable. Continue consistent dosing. |
| Full therapeutic effect | Months 3–6 | Maximum benefit for dementia-related outcomes in clinical trials. |
| Long-term maintenance | 6+ months | Continued benefit with sustained use. Safe for up to 2 years in trials. |
Key Dosing Rules
- Start low: Begin with 120 mg/day for 1–2 weeks
- Increase if tolerated: Move to 240 mg/day divided into two doses
- Never exceed 240 mg/day — no additional benefit at higher doses
- Consistency matters — take at the same times each day
- Take with food — reduces GI side effects
- Be patient — 8–12 weeks minimum for cognitive effects
Quality Standards — 24/6 Standardization
The single most important factor in choosing a ginkgo supplement is standardization. Unstandardized products deliver inconsistent doses of active compounds and may contain harmful levels of ginkgolic acids.
The 24/6 Gold Standard
| Quality Parameter | Standard | Why It Matters |
|---|---|---|
| Flavone glycosides | 24% (quercetin, kaempferol, isorhamnetin) | Primary antioxidant and vasodilatory compounds |
| Terpene lactones | 6% (ginkgolides A, B, C, J + bilobalide) | PAF antagonism, neuroprotection |
| Ginkgolic acid | <5 ppm | Alkylphenol allergen — causes contact dermatitis similar to poison ivy |
| Extraction ratio | 50:1 concentrate from dried leaves | Ensures therapeutic concentration |
Quality Checklist for Consumers
- Label states “standardized to 24% flavone glycosides and 6% terpene lactones”
- Ginkgolic acid content stated as <5 ppm (or listed as “low ginkgolic acid”)
- Third-party testing: USP, NSF, or ConsumerLab verified (preferred)
- Manufacturer provides Certificate of Analysis (CoA) on request
- No proprietary blends hiding actual ginkgo dose
- Clearly states mg of extract per serving (not mg of raw leaf)
What to Avoid
| Red Flag | Why |
|---|---|
| “Ginkgo biloba leaf” without standardization | Unknown active compound content |
| Raw leaf powder capsules | Not concentrated; sub-therapeutic doses likely |
| Ginkgo tea | Inconsistent dosing, low potency, uncontrolled ginkgolic acids |
| Proprietary blends with ginkgo | Cannot verify actual ginkgo dose |
| No ginkgolic acid specification | May contain harmful levels of alkylphenols |
| “Whole herb” ginkgo | Indicates non-extracted, non-standardized product |
Product Comparison
All products below meet 24/6 standardization and provide 120 mg clinical dose per unit. Evaluated on standardization, third-party testing, allergen profile, and value.
| Product | Dose/Unit | Standardization | Key Features | Best For |
|---|---|---|---|---|
| NOW Foods Ginkgo Biloba Double Strength | 120 mg | 24/6, 50:1 extract | Non-GMO verified, excellent price | Best overall value |
| Nature’s Bounty Ginkgo Biloba | 120 mg | 24/6 | Widely available, very affordable | Budget option |
| Jarrow Formulas Ginkgo Biloba | 120 mg | 50:1 concentrated extract | Allergen-friendly, vegan | Quality-focused |
| Doctor’s Best Extra Strength Ginkgo | 120 mg | 24/6 | Vegan, soy-free, gluten-free, 120-ct | Vegan consumers |
| Nature’s Way Ginkgold Max | 120 mg | Proprietary advanced extraction | Premium ginkgo-specific brand | Premium option |
| Nature’s Way Ginkgold Advanced | 60 mg | Proprietary extraction | Lower dose allows precise titration | Gradual dosing |
| Solgar Ginkgo Biloba Leaf Extract | 60 mg | SFP (full potency) extraction | Kosher, 180-ct, premium quality | Solgar loyalists |
| Swanson Ginkgo Biloba Extract | 120 mg | Standardized extract | Lowest price point | Ultra-budget |
💡 Recommendation: For most people, a 120 mg standardized extract taken twice daily (total 240 mg/day) matches the clinical trial protocol. Choose a product with clear 24/6 labeling and, ideally, third-party testing.
For detailed product reviews with pros, cons, and retailer links, see the full HealthSecrets ginkgo biloba guide.
Mechanisms of Action
Ginkgo biloba exerts cognitive benefits through four synergistic mechanisms. This multi-target approach explains its broad efficacy across vascular and neurodegenerative conditions.
| Mechanism | Active Compounds | How It Works | Clinical Relevance |
|---|---|---|---|
| Cerebral blood flow | Flavone glycosides | Vasodilation, endothelin-1 antagonism, microcirculation improvement | Improved oxygen/glucose delivery to brain tissue [6] |
| Antioxidant neuroprotection | Flavone glycosides (quercetin, kaempferol) | Free radical scavenging, lipid peroxidation reduction, mitochondrial protection | Prevents neuronal death from oxidative stress [6][19] |
| Anti-inflammatory | Ginkgolides (terpene lactones) | PAF antagonism, cytokine reduction, immune modulation | Reduces neuroinflammation; also causes bleeding risk [6][18] |
| Neuroprotection | Bilobalide, ginkgolides | Anti-apoptotic effects, mitochondrial stabilization, amyloid-beta modulation | May slow neurodegenerative progression [7][19] |
Bioavailability Notes
- Flavone glycosides reach measurable plasma levels within 1–2 hours (half-life: 2–4 hours) [20]
- Terpene lactones (especially bilobalide) show good oral bioavailability
- Absorption is adequate with or without food; slight improvement with meals
- Phospholipid complexes may enhance bioavailability but are not required at standard doses
- Tea is NOT recommended — inconsistent dosing, low potency, uncontrolled ginkgolic acids
Curated PubMed Research Library
Meta-Analyses & Systematic Reviews
- Müller WE, et al. (2025) — EGb 761 meta-analysis in mild dementia — World J Biol Psychiatry [1]
- Ong Lai Teik D, et al. (2024) — Ginkgo biloba in neuropsychiatric disorders — J Neuropsychiatry [2]
- Nguyen TH, et al. (2025) — Ginkgo drug interactions and bleeding risk — PLOS ONE [4]
- DeKosky ST, et al. (2008) — GEM trial: ginkgo for dementia prevention — JAMA [11]
- Laws KR, et al. (2012) — Ginkgo systematic review and meta-analysis — Human Psychopharmacology [5]
Key RCTs — Dementia & Cognitive Impairment
- Kim HJ, et al. (2024) — Ginkgo in amyloid PET-positive MCI — PMC [7]
- Ihl R, et al. (2012) — EGb 761 in dementia with BPSD — Int Psychogeriatr [14]
- Herrschaft H, et al. (2012) — EGb 761 in dementia with neuropsychiatric symptoms — J Psychiatr Res [15]
- Napryeyenko O, et al. (2007) — EGb 761 in dementia with neuropsychiatric features — Arzneimittelforschung [16]
- Kanowski S, et al. (1996) — Ginkgo in mild-moderate dementia — Pharmacopsychiatry [17]
Drug Interactions & Safety
- Stoddard GJ, et al. (2016) — Ginkgo and warfarin in VA population — PMC [3]
- Nguyen TH, et al. (2025) — Comprehensive drug interaction analysis — PLOS ONE [4]
- Bent S, et al. (2005) — Safety of ginkgo biloba — Pharmacotherapy [18]
Pharmacology & Mechanisms
- Singh SK, et al. (2019) — Neuroprotective mechanisms of ginkgo — Phytomedicine [6]
- Ren J, et al. (2026) — GBE50 alleviates CSVD cognitive impairment — Neuroscience [19]
- Woelkart K, et al. (2010) — Pharmacokinetics of ginkgo biloba compounds — Clin Pharmacokinet [20]
Cognitive Enhancement in Healthy Adults
- Laws KR, et al. (2012) — Ginkgo and cognitive function review — Human Psychopharmacology [5]
- Canter PH, Ernst E (2007) — Ginkgo in healthy volunteers — Psychopharmacology [12]
## Frequently Asked Questions
**Q: What is the best evidence-based ginkgo biloba extract?**
**A:** EGb 761 is the gold-standard ginkgo extract used in virtually all major clinical trials. It is standardized to 24% flavone glycosides and 6% terpene lactones with ginkgolic acid below 5 ppm. Products labeled "24/6 standardized" follow the same profile. A 2025 meta-analysis confirmed EGb 761 at 240 mg/day significantly improves cognition in mild dementia [1].
**Q: Does ginkgo biloba interact with blood thinners?**
**A:** Yes, significantly. Ginkgo's ginkgolides antagonize platelet-activating factor (PAF), potentiating the effects of anticoagulants and antiplatelets. A Veterans Administration study found a hazard ratio of 1.38 for bleeding events with concurrent warfarin use [3]. Never combine ginkgo with warfarin, apixaban, clopidogrel, or aspirin without medical supervision [4].
**Q: How long does ginkgo biloba take to work?**
**A:** Cognitive benefits typically require 8–12 weeks of consistent daily use at 240 mg/day. Circulatory symptoms (dizziness, tinnitus) may improve in 2–4 weeks. Ginkgo works gradually by improving cerebral blood flow and reducing oxidative damage — it is not a stimulant with immediate effects.
**Q: Is ginkgo biloba effective for healthy young adults?**
**A:** The evidence is weak. Systematic reviews have found no convincing evidence that ginkgo improves cognitive performance in healthy individuals under 60 [12]. Benefits are most pronounced in populations with existing cognitive decline or vascular impairment. Healthy adults are better served by optimizing sleep, exercise, and nutrition.
**Q: Can ginkgo biloba prevent Alzheimer's disease?**
**A:** Current evidence does not support ginkgo for Alzheimer's prevention in healthy individuals. The GEM trial (n=3,069) found no benefit over 6+ years [11]. However, a 2024 study found possible disease-modifying effects in patients who already have mild cognitive impairment with amyloid pathology [7].
**Q: What is the 24/6 standardization for ginkgo supplements?**
**A:** The 24/6 standard means the extract contains 24% flavone glycosides (antioxidant, vasodilatory compounds) and 6% terpene lactones (neuroprotective PAF antagonists), matching the EGb 761 clinical trial profile. Products should also have ginkgolic acid below 5 ppm. Without this standardization, the product is unreliable.
**Q: Should you stop ginkgo before surgery?**
**A:** Yes. Stop ginkgo at least 2 weeks before any surgery or invasive dental procedure. The antiplatelet effects of ginkgolides increase bleeding risk during and after procedures. Always inform your surgical team that you take ginkgo [3][4].
References
- Müller WE, et al. “Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia — a meta-analysis.” World Journal of Biological Psychiatry. 2025. https://doi.org/10.1080/15622975.2025
- Ong Lai Teik D, et al. “A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders.” Journal of Neuropsychiatry. 2024.
- Stoddard GJ, et al. “Ginkgo and Warfarin Interaction in a Large Veterans Administration Population.” PMC. 2016. https://doi.org/10.1016/j.ahj.2015.06.017
- Nguyen TH, et al. “Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis.” PLOS ONE. 2025. https://doi.org/10.1371/journal.pone.0315663
- Laws KR, et al. “Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis.” Human Psychopharmacology. 2012;27(6):527-533.
- Singh SK, et al. “Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders.” Neurotherapeutics. 2019;16(3):666-674.
- Kim HJ, et al. “Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment.” PMC. 2024.
- Weinmann S, et al. “Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.” BMC Geriatrics. 2010;10:14.
- von Boetticher A. “Ginkgo biloba extract in the treatment of tinnitus: a systematic review.” Neuropsychiatric Disease and Treatment. 2011;7:441-447.
- Nicolaï SP, et al. “Ginkgo biloba for intermittent claudication.” Cochrane Database Syst Rev. 2013;(6):CD006888.
- DeKosky ST, et al. “Ginkgo biloba for prevention of dementia: a randomized controlled trial.” JAMA. 2008;300(19):2253-2262. https://doi.org/10.1001/jama.2008.683
- Canter PH, Ernst E. “Ginkgo biloba is not a smart drug: an updated systematic review of randomised clinical trials testing the nootropic effects of G. biloba extracts in healthy people.” Human Psychopharmacology. 2007;22(5):265-278.
- Evans JR. “Ginkgo biloba extract for age-related macular degeneration.” Cochrane Database Syst Rev. 2013;(1):CD001775.
- Ihl R, et al. “Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761 in Alzheimer’s disease and vascular dementia.” Pharmacopsychiatry. 2012;45(2):41-46.
- Herrschaft H, et al. “Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features.” J Psychiatr Res. 2012;46(6):716-723.
- Napryeyenko O, Borzenko I. “Ginkgo biloba special extract in dementia with neuropsychiatric features.” Arzneimittelforschung. 2007;57(1):4-11.
- Kanowski S, et al. “Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia.” Pharmacopsychiatry. 1996;29(2):47-56.
- Bent S, et al. “Spontaneous bleeding associated with Ginkgo biloba.” J Gen Intern Med. 2005;20(7):657-661.
- Ren J, et al. “Ginkgo biloba extract GBE50 alleviates cognitive impairment in cerebral small vessel disease.” Neuroscience. 2026.
- Woelkart K, et al. “Pharmacokinetics of bilobalide, ginkgolides A and B after administration of three different Ginkgo biloba preparations in humans.” Clin Pharmacokinet. 2010;49(8):527-538.
Free Tools & Related Resources
📚 On this site:
- 🧠 Brain Health Optimization Resources — Nootropic protocols, brain fog elimination, and cognitive performance tools
- 🧠 Evidence-Based Nootropics Research Database — 10-compound comparison table with evidence grades and dosing protocols
- 🧘 Mental Wellness Natural Toolkit — Comprehensive mental wellness framework
- 😟 Anxiety Relief Toolkit — Evidence-based natural anxiety remedies
- 🐟 Omega-3 Brain Health Resources — DHA vs EPA comparison and dosing protocols
- 💊 Evidence-Based Supplements Database — Complete supplement reference with interaction warnings
- 🌿 Adaptogen Stress Protocols — Curated adaptogen research database
📖 Full guides on HealthSecrets.com:
- Ginkgo Biloba for Brain Health: Evidence-Based Review — Complete ginkgo biloba guide with product reviews
- HealthSecrets Mental Wellness Guide — Comprehensive natural mental wellness strategies
Contributing
We welcome contributions! Please submit a pull request with:
- Peer-reviewed citations (PubMed, Cochrane, NIH preferred)
- Evidence grades for all claims
- Practical, actionable recommendations
© HealthSecrets.com — Evidence-based ginkgo biloba research. For informational purposes only. Not medical advice. Consult a qualified healthcare professional before starting any supplement protocol.